J Eur Acad Dermatol Venereol. "Toxic erythema" and eosinophilia associated to tocilizumab therapy in a COVID-19 patient

[tetano]

J Eur Acad Dermatol Venereol. 2020 May 9. doi: 10.1111/jdv.16620. [Epub ahead of print]
"Toxic erythema" and eosinophilia associated to tocilizumab therapy in a COVID-19 patient.


Sernicola A¹, Carnicelli G¹, Di Fraia M¹, Chello C¹, Furlan C², Muharremi R¹, Paolino G¹, Grieco T¹.

Author information




Abstract

Since the new fatal pneumonia was identified in December 2019 in Wuhan, China, the WHO declared the infection a health emergency of international concern. The novel ss-RNA ?-coronavirus (SARS-CoV-2) spreads through airborne and direct contagion; virulence is high in the elderly and in patients with diabetes, chronic pulmonary, cardiovascular and neoplastic diseases. SARS-CoV-2 ssRNA is recognized by intracellular Pattern Recognition Receptors (PRRs), which trigger NF-kB - the master regulator of inflammation - and Interferon Regulatory Factors (IRFs)¹ .
This article is protected by copyright. All rights reserved.



KEYWORDS:

COVID-19; drug eruption; eosinophilia; tocilizumab


PMID:32386438DOI:10.1111/jdv.16620